Literature DB >> 15505605

Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity?

Parameswaran Hari1, Brent Logan, William R Drobyski.   

Abstract

The graft-versus-leukemia (GVL) effect is often coexpressed with graft-versus-host disease (GVHD), although the temporal kinetics of these responses have not been critically examined. To evaluate this question in the absence of the confounding effects of the conditioning regimen, 23 patients who received donor lymphocyte infusions from HLA-identical siblings and subsequently developed GVHD and/or a GVL response were studied to determine whether these were temporally synchronous events. The GVL effect occurred significantly earlier than GVHD, being that 19 of 23 patients had a sustained GVL response that antedated the onset of clinical GVHD. The median difference between time to GVL and graft-versus-host (GVH) reactivity in the entire cohort was 14 days. There was no correlation between total T-cell dose and the relative onset of GVL versus GVH reactivity, indicating that temporal dissociation of GVL and GVH responses was not a function of the absolute number of infused donor T cells. These data support existing murine bone marrow transplantation studies indicating that GVL and GVH responses are not temporally synchronous events and raise the possibility that targeted elimination of alloreactive donor T cells after bone marrow transplantation may be an effective strategy for the separation of GVL/GVH reactivity.

Entities:  

Mesh:

Year:  2004        PMID: 15505605     DOI: 10.1016/j.bbmt.2004.07.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  3 in total

1.  Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease.

Authors:  Yi Zhang; Ashley R Sandy; Jina Wang; Vedran Radojcic; Gloria T Shan; Ivy T Tran; Ann Friedman; Koji Kato; Shan He; Shuaiying Cui; Elizabeth Hexner; Dale M Frank; Stephen G Emerson; Warren S Pear; Ivan Maillard
Journal:  Blood       Date:  2010-09-24       Impact factor: 22.113

2.  CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy.

Authors:  Hyung Bae Park; Ji Eun Lee; Yu Mi Oh; Sang Jin Lee; Hyeon-Seok Eom; Kyungho Choi
Journal:  Exp Mol Med       Date:  2017-07-28       Impact factor: 8.718

3.  Neither Donor nor Recipient Mitochondrial Haplotypes Are Associated with Unrelated Donor Transplant Outcomes: A Validation Study from the CIBMTR.

Authors:  Logan G Spector; Stephen R Spellman; Bharat Thyagarajan; Kenneth B Beckman; Cody Hoffmann; John Garbe; Theresa Hahn; Lara Sucheston-Campbell; Michaela Richardson; Todd E De For; Jakub Tolar; Michael R Verneris
Journal:  Transplant Cell Ther       Date:  2021-06-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.